Sana Biotechnology Inc vs First Trust Cloud Computing ETF — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while First Trust Cloud Computing ETF trades at $163. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SKYY | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | — |
52-Week High | $5.92 | $161.09 |
52-Week Low | $2.68 | $104.16 |
Enterprise Value | $1.05B | — |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
SKYY (First Trust Cloud Computing ETF) trades at $162.56, up 1.11% with strong technical momentum as moving averages signal bullish sentiment. The ETF provides diversified exposure to cloud infrastructure, software, and AI companies, benefiting from secular trends in digital transformation. Recent news highlights institutional interest in cloud computing ETFs as AI adoption accelerates.
The outlook remains positive given cloud migration trends and AI infrastructure investments, though overbought technical indicators suggest potential near-term consolidation. Key risks include regulatory developments in Europe's tech sovereignty initiatives and competitive pressures in the cloud computing sector.
Trailing returns across standard periods
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →